Biotechnology

OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies

NEW YORK, June 29, 2021 /PRNewswire/ -- OnCusp Therapeutics (or "OnCusp"), a global biopharmaceutical company focused on translating cutting-edge research assets into innovative oncology therapeutics, announced that it has officially commenced operations both inNew York and Shanghai. OnCusp succ...

2021-06-30 09:29 1284

Hanmi Pharmaceutical finds new innovative potential for "Efpeglenatide"

SEOUL, South Korea, June 29, 2021 /PRNewswire/ -- Hanmi Pharmaceutical (hereinafter Hanmi) recently announced that its new, long-acting diabetes biologic drug, efpeglenatide, was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the resul...

2021-06-29 21:00 1550

I-Mab Announces Upcoming Participation at July Conference

SHANGHAI and GAITHERSBURG, Md., June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conference in July. D...

2021-06-29 20:00 8161

First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON

* Novel and one-time intravitreal injection of ND4 gene therapy for the treatment of LHON potentially restored vision * Phase I/II/III clinical trial expected to enroll patients with LHON due to ND4 mutation WUHAN, China and SAN DIEGO, June 28, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd...

2021-06-28 21:33 1474

International experts join Microba Life Sciences inaugural IBD Advisory Panel

BRISBANE, Australia, June 28, 2021 /PRNewswire/ -- Precision microbiome science company,Microba Life Sciences , has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes f...

2021-06-28 21:00 1468

ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury

DAEJEON, South Korea, June 28, 2021 /PRNewswire/ -- Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc. in collaboration withYonsei University of Seoul, South Korea. ...

2021-06-28 20:00 1287

InnoCare Announces Breakthrough Therapy Designation of Orelabrutinib by US FDA for Treatment of R/R MCL

BEIJING, June 28, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib for the trea...

2021-06-28 16:02 10285

Sanyou Biopharmaceuticals completes series B financing and secures its leading role in innovative antibody drug discovery

SHANGHAI, June 26, 2021 /PRNewswire/ -- Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and ...

2021-06-26 23:00 3004

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

* Independent modelling estimates the PromarkerD predictive test for diabetic kidney disease (DKD) would increase the quality of care and could save US payers almostUSD400 billion over 10 years * The US is home to 31 million adults with diabetes who are at risk of DKD - cost savings stem from...

2021-06-25 23:30 2597

Vazyme Brings COVID-19 Testing Solutions at Medlab 2021

DUBAI, UAE, June 25, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) showcased its lineup of COVID-19 testing solutions and its point-of-care testing (POCT) in vitro diagnostic instruments at the 2021 Medlab Middle East, an industry-leading medical labo...

2021-06-25 15:31 1334

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...

2021-06-25 15:06 1374

Samsung Biologics Issues Its First Annual Sustainability Report

* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...

2021-06-25 09:01 22338

TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, Demonstrating How to Keep Probiotics Alive without Refrigeration for over 1 year

TAIPEI, June 24, 2021 /PRNewswire/ -- To keep enough probiotics alive in products, sellers and consumers must meet the storage conditions, especially storagetemperature. Since most live probiotics can only survive in a low-temperature environment, most probiotic products, especially lactic acid ...

2021-06-25 09:00 1482

Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections

* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...

2021-06-23 19:28 1199

100 Billion Live Probiotics in a Bottle: TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, After 20 Years of Research

TAIPEI, June 23, 2021 /PRNewswire/ -- Probiotic drinks now available on the market often cannot fully exert the effect despite the content of lactic acid bacteria because live bacteria in thedrinks can be killed over time or due to poor storage, which causes the numbers of live probiotics consume...

2021-06-23 14:28 1387

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

BEIJING and BOSTON, June 22, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens o...

2021-06-23 04:16 1391

Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia

SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...

2021-06-22 22:32 9280

Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.

NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...

2021-06-20 21:00 2655

InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma

BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...

2021-06-18 17:12 13550

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...

2021-06-17 15:41 13616
1 ... 84858687888990 ... 113